Boehringer Ingelheim has secured approval from the United States Food and Drug Administration for Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. The decision follows earlier FDA clearance for Jascayd in idiopathic pulmonary fibrosis and now marks the first time a preferential PDE4B inhibitor with dual immunomodulatory and antifibrotic effects has been approved for use across broader fibrosing interstitial lung diseases. The latest nod is based on results from the Phase III FIBRONEER-ILD trial, the largest study conducted in this indication to date, showing a statistically significant slowdown in lung function decline.

The newly approved indication represents an important shift in how regulators and clinicians approach fibrosing lung diseases that fall outside classic idiopathic pulmonary fibrosis, including autoimmune interstitial lung disease, hypersensitivity pneumonitis, and other overlapping conditions. With progressive pulmonary fibrosis estimated to affect as many as 100,000 people in the United States and over 5 million globally, the approval fills a longstanding treatment gap.

The PDE4B mechanism introduces a differentiated strategy in fibrotic lung disease management

Jascayd’s underlying mechanism is a key departure from the tyrosine kinase inhibition model exemplified by drugs such as nintedanib. By selectively targeting phosphodiesterase 4B, nerandomilast modulates intracellular signaling pathways involved in immune activation and fibrotic remodeling. This selectivity may offer improved tolerability while preserving antifibrotic activity.

Industry analysts tracking pulmonary fibrosis therapeutics have noted the significance of a drug that spans both idiopathic and progressive disease subtypes without relying on specific underlying etiologies. This could reshape treatment paradigms for clinicians dealing with heterogeneous patient populations. The approval also serves as regulatory validation for PDE4B as a clinically meaningful antifibrotic target, potentially prompting development of adjacent agents in the same class.

How FIBRONEER-ILD outcomes support real-world adoption—and what remains unproven

The FIBRONEER-ILD study met its primary endpoint of reduced decline in forced vital capacity at Week 52. Patients receiving Jascayd 18 mg and 9 mg experienced mean FVC reductions of 86 mL and 69 mL respectively, compared to a 152 mL decline in the placebo group. These differences translate into treatment effects of 65 to 83 mL over one year, closely aligning with previous benchmarks from antifibrotic therapies in idiopathic pulmonary fibrosis.

However, the key secondary composite endpoint—time to acute exacerbation, respiratory hospitalization, or death—did not reach statistical significance, although trends favored the Jascayd arms. The hazard ratio for the 18 mg dose was 0.77 and 0.88 for the 9 mg dose. Exploratory analysis suggested a nominally significant reduction in acute exacerbation risk for the 18 mg group, and mortality trends through 114 weeks were similarly favorable, but these were not prespecified for multiplicity control.

Clinicians are likely to view these results as a credible foundation for therapeutic use but will expect confirmatory data through real-world evidence and long-term registry follow-up. The absence of definitive survival benefit could slow adoption in some subgroups, especially in the context of price negotiations or payer step therapy protocols.

Safety and tolerability profile offers a key differentiator, particularly in older or comorbid populations

The tolerability profile of Jascayd may prove to be one of its strongest clinical advantages. Diarrhea was the most common adverse event, particularly in patients taking background nintedanib, but rates of permanent discontinuation due to side effects were low and comparable to placebo. Most gastrointestinal events occurred within the first three months of treatment and were categorized as mild to moderate in intensity.

Notably, in patients not receiving concomitant antifibrotic therapy, the discontinuation rate due to diarrhea was just 1 percent. This contrasts with higher discontinuation rates historically observed with tyrosine kinase inhibitors like nintedanib. The option to use Jascayd as monotherapy or in combination regimens could enable more individualized therapy plans, especially in patients with overlapping autoimmune disorders or those with reduced baseline performance status.

Still, some safety variables remain undercharacterized, including the interaction potential of Jascayd with immunosuppressive drugs often used in autoimmune interstitial lung diseases. The absence of a boxed warning or contraindications in the label suggests a high regulatory confidence in the risk–benefit balance, but post-marketing pharmacovigilance will play a central role in identifying long-tail adverse events.

Regulatory precedent may prompt broader shifts in clinical trial design for interstitial lung disease

The approval of Jascayd in progressive pulmonary fibrosis may influence future regulatory and trial strategies across pulmonary medicine. The decision indicates that the United States Food and Drug Administration is willing to consider antifibrotic efficacy across etiologically diverse subtypes of interstitial lung disease, provided the underlying progression criteria are met.

This could unlock new trial designs based on disease behavior rather than diagnostic classification. Trials evaluating agents across autoimmune interstitial lung disease, hypersensitivity pneumonitis, and unclassifiable fibrosis might now proceed without needing indication-specific approvals, streamlining development pipelines. In addition, the use of forced vital capacity as a primary endpoint continues to hold regulatory weight, reinforcing its role in future trial protocols.

However, regulatory observers note that absence of superiority on secondary endpoints such as hospitalization or mortality will likely limit the speed of payer coverage decisions. Companies entering the space will need to weigh the benefits of early FVC-based approvals against the commercial risks of ambiguous survival data.

Market expansion, payer access, and global timelines to watch

Jascayd’s dual indication sets Boehringer Ingelheim up for a leading position in the fibrosing interstitial lung disease market. With up to 100,000 progressive pulmonary fibrosis patients in the United States alone, commercial analysts project significant uptake if payer contracts are favorable. The company’s public remarks suggest that access discussions are already underway.

Outside the United States, regulatory submissions are expected in major global markets throughout 2026. Regions such as the European Union and Japan may take particular interest in the product given the broad prevalence of progressive pulmonary fibrosis across mixed etiologies. As many as half of patients remain untreated following diagnosis, often due to lack of label coverage or insufficient clinical trial data for their specific subtype. Jascayd’s approval may address this access barrier.

Pulmonologists may also view Jascayd as a trigger to expand early diagnostic efforts. With diagnosis of progressive pulmonary fibrosis often delayed by up to two years, the availability of a new therapy could drive earlier specialist referrals and more routine high-resolution CT imaging among at-risk populations.

Implications for competitive positioning and future development

Boehringer Ingelheim’s success with Jascayd creates new strategic pressure on other fibrosis-focused biopharmaceutical companies. Developers of tyrosine kinase inhibitors, monoclonal antibodies, and other anti-inflammatory or antifibrotic agents may be compelled to shift trial design strategies to incorporate broader endpoints or behavior-based subgroups. Companies that failed to show efficacy in prior IPF-only studies may now revisit those assets for use in broader populations.

The approval also opens the door for combination strategies, particularly in patients where antifibrotic monotherapy produces only modest benefit. Trials exploring nerandomilast alongside nintedanib, pirfenidone, or newer inhaled therapies could redefine treatment algorithms. Given the acceptable tolerability profile and non-overlapping mechanism of action, such studies may be feasible without substantial safety compromise.

At a broader level, this regulatory milestone could fuel investment into fibrosis drug discovery across other organ systems. The PDE4B target pathway has relevance in kidney, liver, and systemic fibrotic disorders, and Jascayd’s success may act as a clinical and commercial validation point for programs beyond the lung.

  antifibrotic therapy, Boehringer Ingelheim, FIBRONEER-ILD, fibrosing lung disease, idiopathic pulmonary fibrosis, Jascayd, nerandomilast, PDE4B inhibitor, progressive pulmonary fibrosis